Managing diabetes may soon become more convenient for many patients in India. Awiqli (Insulin Icodec), the country’s first once-weekly basal insulin, is now available for adults with Type 1 and Type 2 diabetes (when prescribed). Developed by Novo Nordisk, this innovative insulin reduces the number of basal insulin injections from 365 to just 52 per year, making long-term diabetes management simpler for eligible patients.
Whether you’re a healthcare professional, pharmacy student, or someone living with diabetes, this guide explains everything you need to know about Awiqli, including its benefits, price, usage, and safety.
Quick Summary (AI Overview)
Awiqli (Insulin Icodec) is a once-weekly basal insulin developed by Novo Nordisk and now available in India. It helps adults with Type 1 and Type 2 diabetes maintain blood glucose control with only one injection per week. By reducing injection frequency, Awiqli may improve convenience and treatment adherence when used under medical supervision.
Overview
| Particular | Details |
|---|---|
| Brand Name | Awiqli |
| Generic Name | Insulin Icodec |
| Developed By | Novo Nordisk |
| Drug Class | Ultra-long-acting Basal Insulin |
| Dosing | Once Weekly |
| Indication | Adults with Type 1 & Type 2 Diabetes |
| Route | Subcutaneous Injection |
| Availability | India |
What is Awiqli?
Awiqli is the brand name of Insulin Icodec, an ultra-long-acting basal insulin designed to provide stable blood glucose control for an entire week with a single injection.
Unlike traditional basal insulin that requires daily administration, Awiqli is injected once every seven days, helping simplify insulin therapy for eligible adults.
How Does Awiqli Work?
Basal insulin provides continuous background insulin throughout the day and night.
Awiqli slowly releases insulin over seven days, helping maintain consistent glucose levels and reducing the need for daily injections.
Patients should administer the injection on the same day every week as directed by their healthcare provider.
Key Features of Awiqli
- Only one injection per week
- Reduces annual injections from 365 to 52
- Long-lasting glucose control
- Convenient prefilled insulin pen
- Designed to improve treatment adherence
- Suitable for eligible adults with diabetes
Available Variants and Price in India
| Variant | Strength | Approx. Price |
|---|---|---|
| 1 mL Pen | 700 Units | ₹2,611 |
| 3 mL Pen | 2,100 Units | ₹7,833 |
Prices may vary depending on the pharmacy and location.
Who Can Use Awiqli?
Awiqli may be prescribed for:
Adults with Type 1 Diabetes
Used together with rapid-acting (mealtime) insulin.
Adults with Type 2 Diabetes
For patients who require basal insulin therapy as recommended by their doctor.
Eligibility
Awiqli is indicated for:
- Adults with Type 1 Diabetes
- Adults with Type 2 Diabetes requiring basal insulin
- Patients advised by a qualified healthcare professional
Why Does It Matter for India?
India has one of the largest populations living with diabetes worldwide.
Common challenges include:
- Fear of daily injections
- Poor adherence to insulin therapy
- Delayed insulin initiation
- Busy lifestyles affecting treatment compliance
A once-weekly insulin has the potential to reduce treatment burden and improve patient convenience.
Clinical Benefits
Clinical studies have shown that Insulin Icodec can provide blood glucose control comparable to daily basal insulin in many adults when used appropriately.
Potential benefits include:
- Improved treatment adherence
- Fewer injections
- Better convenience
- Simplified weekly schedule
- Comparable HbA1c reduction
Advantages of Awiqli
| Benefit | Description |
|---|---|
| Weekly dosing | Only one injection every week |
| Better convenience | Easier treatment routine |
| Improved adherence | Lower injection burden |
| Stable glucose control | Continuous basal insulin coverage |
| Prefilled pen | Easy administration |
Possible Limitations
Although Awiqli offers many benefits, it may not be suitable for everyone.
Patients should remember:
- Requires careful dose adjustment
- Blood glucose monitoring remains essential
- Missing a weekly dose may affect blood sugar control
- Must only be used under medical supervision
Possible Side Effects
Like other insulin products, Awiqli may cause:
- Hypoglycemia (low blood sugar)
- Injection-site reactions
- Weight gain
- Allergic reactions (rare)
Seek immediate medical attention if severe symptoms occur.
Safety Precautions
Always remember:
- Never self-adjust the dose.
- Use only as prescribed.
- Monitor blood glucose regularly.
- Learn proper injection technique.
- Store the insulin according to manufacturer instructions.
- Never share insulin pens.
Comparison: Daily Basal Insulin vs Awiqli
| Feature | Daily Basal Insulin | Awiqli |
|---|---|---|
| Frequency | Daily | Weekly |
| Injections/Year | 365 | 52 |
| Convenience | Moderate | High |
| Treatment Burden | Higher | Lower |
Why Should Pharmacy Students Know About Awiqli?
For B.Pharm, D.Pharm, M.Pharm, GPAT, NIPER, Pharmacist, and Drug Inspector aspirants, Awiqli is an important advancement in diabetes pharmacotherapy.
Understanding its mechanism, advantages, and clinical applications is valuable for:
- Competitive exams
- Clinical pharmacy practice
- Pharmacology subjects
- Patient counseling
- Hospital pharmacy
Frequently Asked Questions (FAQs)
1. What is Awiqli?
Awiqli is a once-weekly basal insulin containing Insulin Icodec for adults with diabetes.
2. How often is Awiqli injected?
It is injected once every week on the same day each week.
3. Can Awiqli replace all insulin injections?
No. Patients with Type 1 diabetes still require rapid-acting mealtime insulin.
4. Is Awiqli available in India?
Yes. Awiqli is now available in India for eligible adult patients as prescribed by healthcare professionals.
5. What is the generic name of Awiqli?
Its generic name is Insulin Icodec.
6. Does Awiqli cure diabetes?
No. It helps manage blood glucose levels but does not cure diabetes.
7. What are the common side effects?
The most common side effect is hypoglycemia (low blood sugar). Other side effects may include injection-site reactions and weight gain.
8. Should patients consult a doctor before using Awiqli?
Yes. Awiqli should only be started and adjusted under the supervision of a qualified healthcare professional.
Recommended Products
